{"id":"W3170977860","doi":"10.1200/jco.2021.39.15_suppl.5515","title":"Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; University of Manitoba; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; BRCA mutation; Clinical endpoint; Oncology; Tolerability; Ovarian cancer; Discontinuation; Gastroenterology; Cancer; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007319688,0.0003064472,0.0005181671,0.0002009133,0.0001467305,0.0005296032,0.0002367869,0.0002815464,0.001806369],"category_scores_gemma":[0.000622442,0.0002114182,0.0004770808,0.0002867103,0.0002688999,0.0003130763,0.0002963504,0.0006868336,0.0002418862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005875108,"about_ca_system_score_gemma":0.0006464953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003553412,"about_ca_topic_score_gemma":0.001328916,"domain_scores_codex":[0.9997502,0.0001217812,0.00002088818,0.00004847947,0.00002913381,0.00002964175],"domain_scores_gemma":[0.9995257,0.00009746541,0.0001892141,0.00002769527,0.00001770683,0.0001421626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5287579,0.01124181,0.1872788,0.001331103,0.001963873,0.0004938085,0.0002830907,0.003104337,0.02350144,0.0002687479,0.003851112,0.237924],"study_design_scores_gemma":[0.2764723,0.3781269,0.3138489,0.0002955537,0.002419637,0.002328878,0.000292014,0.004413445,0.007761398,0.0007451201,0.01324254,0.00005332021],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99632,0.001981649,0.0001587496,0.000114363,0.00001363174,0.0002429227,0.0005437675,0.00001381022,0.0006111254],"genre_scores_gemma":[0.997238,0.0007839038,0.0003442773,0.0001800664,0.00003110994,0.0001900767,0.0008401474,0.000003664054,0.0003887165],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001806369,"threshold_uncertainty_score":0.006042957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06458866069387688,"score_gpt":0.4171793893224604,"score_spread":0.3525907286285835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}